摘要
目的探讨沙利度胺、环磷酰胺和地塞米松联合治疗复发性、难治性多发性骨髓瘤的疗效。方法将我院18例复发性、难治性多发骨髓瘤患者,应用沙利度胺、环磷酰胺和地塞米松联合治疗后进行疗效分析评价。结果 18例复发性、难治性多发性骨髓瘤经沙利度胺、环磷酰胺和地塞米松联合治疗后临床转归,部分缓解(PR)11例占61.1%、进步(PD)3例占16.7%、无效(NC)4例占22.2%。结论沙利度胺、环磷酰胺和地塞米松联合治疗复发性、难治性多发性骨髓瘤疗效可靠。
Objective To understand the thalidomide cyclophosphamide and dexamethasone in the treatment of relapsed and refractory multiple myeloma effect. Methods Totally 18 cases in our hospital with relapsed and refractory multiple myeloma patients, application of thalidomide cyclophosphamide and dexamethasone combination therapy after curative effect analysis and evaluation. Results 18 patients with relapsed and refractory multiple myeloma after thalidomide, cyclophosphamide and dexamethasone combined clinical outcome aider treatment to partial response the 11 cases accounted for 61.1% progressive disease in 3 cases accounted for 16.7%,invalid accounting for 4 cases 22.2%. Conclusion Thalidomide, cyclophosphamide and dexamethasone in the treatment of relapsed and refractory multiple myeloma and reliable.
出处
《中国医药指南》
2013年第21期416-417,共2页
Guide of China Medicine
